Selank vs. Semax is one of the most frequently compared pairings among peptides researched for their impact on brain function, cognitive abilities, stress resilience, and neuroprotection. Both synthetic peptides were developed in Russia and are widely analysed for their potential effects on neurological functions, cognitive processes, and the body's adaptation to stress. Although they share some similarities, such as the possibility of intranasal administration, potential neuroprotective properties, and interaction with signalling pathways in the brain, they were designed with different applications in mind and possess distinct biological profiles. If you want to learn more about Selank, read our detailed guide: https://bioevidencehub.com/peptyd-selank/.
Semax was developed based on a fragment of adrenocorticotropic hormone (ACTH), whereas Selank is derived from the immunoregulatory peptide tuftsin and was modified by adding the Pro-Gly-Pro sequence, which increases its stability and prolongs its biological activity [1–4]. As a result, Semax is most commonly associated with cognitive function support and neuroprotection, while Selank is primarily studied for its regulation of anxiety, stress resistance, and emotional balance.
Quick Comparison: Selank vs Semax
| Feature | Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin-A | ACTH (4-10) |
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Main research area | Anxiety, stress resilience, emotional regulation | Cognitive functions, memory, neuroprotection |
| Key mechanisms | GABA modulation, inhibition of enkephalinase, regulation of BDNF | Modulation of dopamine and serotonin, increased BDNF, neuroprotection |
| Effects studied | Anxiolytic, anti-stress, nootropic, immunomodulatory | Nootropic, neuroprotective, supporting cognitive function |
| Clinical research areas | Generalized anxiety disorder, neurasthenia, anxiety states | Recovery from a stroke, cognitive impairment, cerebrovascular diseases |
| Intranasal administration | Yes | Yes |
| BDNF Regulation | Yes | Yes |
| Sedative effect | Usually unobserved | Usually unobserved |
| The most common area of interest | Anxiety, stress management, emotional stability | Memory, concentration, learning, neuroprotection |
What is the main difference between Selank and Semax?
The main difference between Selanek and Semax lies in the main focus of their research.
Selank has been studied primarily for its anxiolytic effects, its ability to increase stress resistance, regulate emotions and promote a sense of calm. Research suggests that it may influence GABA signalling, inhibit the enzymes responsible for the breakdown of enkephalins, and regulate neurotrophic factors associated with mood and emotional processing [1–5].
Semax, on the other hand, has been studied more extensively in relation to learning, memory, attention, cognitive performance, neuroprotection and the promotion of recovery following neurological damage. Experimental studies indicate that Semax may increase levels of brain-derived neurotrophic factor (BDNF), influence TrkB signalling, promote neuronal survival and modulate dopamine and serotonin activity [6–12].
Put simply, Selank is often regarded as a „calming peptide”, whilst Semax is seen as a „peptide that supports concentration and cognitive function”.
Is Selank better than Semax for anxiety?
Based on the available scientific research, Selank appears to have a stronger research basis in the context of anxiety-related applications.
Clinical trials involving patients suffering from generalised anxiety disorder (GAD) and neurasthenia showed that Selank produced anxiolytic effects comparable to those of the benzodiazepine medazepam. Researchers also observed anti-asthenic effects and mild psychostimulant properties, enabling participants to remain alert and mentally active without many of the side effects characteristic of traditional anti-anxiety medicines [13].
Laboratory studies suggest that Selank acts as a positive allosteric modulator of GABA receptors, which may contribute to its anxiolytic effects. Additionally, it has been shown to inhibit enzymes responsible for the breakdown of endogenous enkephalins, potentially supporting stress resistance and emotional stability [2,3].
For researchers interested in the topics of anxiety, nervous tension, stress or emotional regulation, Selank now has stronger research facilities at its disposal.
Is Semax Better Than Selank for Cognitive Function?
Semax has accumulated a larger number of studies concerning cognitive function, memory, attention, learning and neuroprotection.
Experimental studies have shown that Semax can increase BDNF expression, improve signalling in the hippocampus, support learning and memory processes, protect neurons from ischaemic damage, and influence dopaminergic and serotonergic pathways [6–10].
Semax has also been studied in post-stroke rehabilitation, where improvements in neurological recovery and functional outcomes have been observed. Further studies suggest that it regulates genes associated with inflammatory processes, the immune response, blood vessel function and neuronal repair following brain injury [8–12].
Given this broader scope of research into cognitive function, Semax is generally regarded as a peptide that is more specifically designed to support cognitive processes.
How Do Selank and Semax Affect the Brain?
Both peptides influence neuroplasticity and neuronal communication, but they employ partly different biological mechanisms.
Selank appears to regulate GABA receptor activity, influence BDNF expression, inhibit the degradation of enkephalins, and modulate the expression of genes associated with neurotransmission and the functioning of the immune system. These mechanisms may account for its anxiolytic effects, as well as its role in supporting stress resilience and cognitive function [2–5,14].
Semax, on the other hand, exerts a stronger effect on dopaminergic, serotonergic, neurotrophic and neuroprotective pathways. Research suggests that it increases BDNF production, enhances TrkB signalling, regulates inflammatory responses and supports neuronal survival following neurological damage [6–12].
Although both peptides can support brain health, they appear to focus on different aspects of neurological function.
Can Selank and Semax be used together?
Selank and Semax are often discussed together as they act on complementary systems within the brain.
The theoretical justification for such a combination is relatively simple. Semax can support attention, memory, learning, and neuroprotection, whereas Selank can help regulate stress, anxiety, and emotions. As a result, both peptides could support both cognitive performance and psychological resilience.
It should be emphasised, however, that controlled clinical trials assessing the simultaneous use of Selank and Semax are currently very limited. For this reason, there is insufficient scientific evidence to determine whether the combination of both peptides provides better effects than using each of them separately.
Which is Better: Selank or Semax?
None of these peptides are objectively „better” as they were developed for different research purposes.
If the main focus of the research is anxiety, stress adaptation, emotional balance or anti-anxiety mechanisms, Selank currently has stronger scientific support.
Whereas if the subject of interest is memory, learning, concentration, neuroprotection, stroke recovery, or neuroplasticity, Semax has gathered more scientific evidence.
Many researchers view these compounds as complementary peptides rather than direct competitors, as they influence different neurological and psychological processes.
What Reddit Users Say About Selank and Semax
Discussions on Reddit and other online communities often describe Selank as the „peptide of calm” and Semax as the „peptide of focus”.
Users often describe Selank as supporting relaxation, emotional stability, and the reduction of perceived anxiety without a clear sedative effect. Semax, on the other hand, is sometimes described as a means of improving clarity of thought, concentration, motivation, and productivity.
However, it is worth remembering that these are purely anecdotal accounts and should not be treated as the equivalent of clinical evidence. Controlled scientific studies remain a much more reliable source of information.
Summary
Selank and Semax are among the best-researched neuroactive peptides developed in Russia, however, they were created with different applications in mind. Selank is primarily studied for its anxiolytic, emotional regulation, and stress resilience-enhancing properties, while Semax is mainly analysed in the context of improving cognitive function, memory, neuroprotection, and neurological regeneration.
Current knowledge suggests that Selank may be a better choice for research into anxiety and emotional balance, whereas Semax appears to be more suitable for research into memory, concentration, learning, and neuroplasticity. Rather than competing with each other, both peptides are often seen as complementary research tools affecting various aspects of brain function.
Disclaimer
This article is for educational and informational purposes only. Selank and Semax are research peptides, and the scientific literature on their effects is constantly evolving. The information presented is a summary of laboratory, preclinical, and clinical research findings and should not be interpreted as medical advice, therapeutic recommendation or confirmation of efficacy.
For research purposes only: The Selank and Semax products offered by Semax Polska are intended solely for laboratory and scientific research. They are not authorised for human consumption or for use for medical, diagnostic, therapeutic or prophylactic purposes. All research materials should be used in accordance with applicable legislation and the guidelines of the institutions conducting scientific research.
References
[1] Vyunova, Tatiana V., Lioudmila Andreeva, Konstantin Shevchenko, and Nikolay Myasoedov. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Zozulya, A. A., Kost, N. V., Sokolov, O. Yu., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Yu. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[3] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Yu., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalised Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[4] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Ya., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in the Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[5] Andreeva, L. A., Nagaev, I. Yu., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Ya., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[6] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotonergic Brain Systems in Rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[7] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax Regulates BDNF and TrkB Expression in the Rat Hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[8] Dolotov, O. V., Karpenko, E. A., Seredenina, T. S., Inozemtseva, L. S., Levitskaya, N. G., Zolotarev, Y. A., Kamensky, A. A., Grivennikov, I. A., Engele, J., & Myasoedov, N. F. (2006). Semax binds specifically and increases BDNF protein levels in rat basal forebrain.. Journal of Neurochemistry, 97(Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x
[9] Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The Efficacy of Semax in Patients at Different Stages of Ischaemic Stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
[10] Medvedeva, E. V., Dmitrieva, V. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2017). Semax Regulates Expression of Immune Response Genes during Ischemic Brain Injury in Rats. Molecular Genetics and Genomics, 292(3), 635–653. https://doi.org/10.1007/s00438-017-1297-1
[11] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). The Peptide Semax Affects Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischaemia. BMC Genomics, 15, 228. https://doi.org/10.1186/1471-2164-15-228
[12] Sudarkina, O. Y., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Remizova, J. A., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2021). Brain Protein Expression Profile Confirms the Protective Effect of Semax in Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 22(12), 6179. https://doi.org/10.3390/ijms22126179
[13] Seredyuk, A. V., Levitskiy, G. N., Myasoedov, N. F., & Skvortsova, V. I. (2007). Clinical Evaluation of Semax in Motor Neuron Disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 107(4), 29–39. https://pubmed.ncbi.nlm.nih.gov/18379501/
[14] Kost, N. V., Sokolov, O. Yu., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined Action of Benzodiazepine Tranquillisers and Peptide Anxiolytic Selank in BALB/c Mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783